Risks for acute leukemia

Some things can affect your risk, or chance, of developing cancer. Certain behaviours, substances or conditions can increase or decrease the risk. Most cancers are the result of many risks. But sometimes cancer develops in people who don't have any risks.

Acute leukemia includes 2 types of leukemia – acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Some risks may be different for ALL and AML, and some may be the same.

The risk of developing AML increases with age. It usually occurs in people who are 65 and older. ALL is more common in children and in adults over the age of 50.

Men develop acute leukemia slightly more often than women. We need more research and can't say at this time what the risk is for transgender, non-binary and gender-diverse people.

The following can increase your risk for acute leukemia.

High levels of radiation

There is convincing evidence that coming into contact with high levels of radiation, such as radiation from nuclear reactor accidents, is a risk for acute leukemia. Most leukemias that develop after exposure to radiation are AML rather than ALL.

Previous radiation therapy

There is convincing evidence that radiation therapy given in the past to treat cancer or other health conditions increases the risk of acute leukemia. Having had both radiation therapy and chemotherapy to treat cancer increases the risk more than having had radiation therapy alone.

This risk is higher for AML than for ALL.

Previous chemotherapy

There is convincing evidence that certain chemotherapy drugs or drug combinations increase the risk of developing AML, but the risk is very low. The benefits of having chemotherapy to treat cancer far outweigh this risk.

The following types of chemotherapy drugs and combinations are known to increase the risk of AML:

  • alkylating agents (especially thiotepa, procarbazine, dacarbazine, temozolomide)

  • topoisomerase II inhibitors (epirubicin, mitoxantrone, etoposide)
  • platinum drugs (cisplatin, carboplatin)
  • carmustine (also called BCNU)
  • lomustine (also called CCNU)
  • semustine (also called methyl-CCNU)
  • MOPP – a drug combination with mechlorethamine hydrochloride, vincristine, procarbazine and prednisone

Having both chemotherapy and radiation therapy to treat cancer increases the risk of developing AML even more than having just chemotherapy alone.

Certain blood disorders

People with a history of the following blood disorders have a higher risk of developing AML:

These blood disorders can change and become AML (called a transformation). But not everyone with these blood disorders will develop AML.

Genetic conditions

A genetic condition is a disease caused by a change (mutation) in one or more genes. Having certain genetic conditions increases the risk of developing acute leukemia, especially in childhood.

The following inherited genetic conditions increase the risk of both ALL and AML.

Down syndrome is a condition caused by an extra (third) copy of chromosome 21. It causes different birth defects, intellectual disability, a characteristic facial appearance and poor muscle tone in infancy.

Bloom syndrome is a condition caused by a mutations in a certain chromosome. Signs include shorter than average height, a high-pitched voice and a characteristic facial appearance.

Ataxia-telangiectasia (AT) is a rare disease that affects the nervous system, immune system and other body systems. Signs and symptoms include loss of balance, poor coordination, frequent infections, red eyes (due to widening of blood vessels) and abnormal eye movements.

Li-Fraumeni syndrome is an condition that is associated with an increased risk of developing many different cancers in both adults and children.

Neurofibromatosis type 1 is a condition that affects the nervous system. It affects the development and growth of nerve cells, causes tumours to grow on nerves and may cause other abnormalities in muscles, bone and skin.

The following genetic conditions increase the risk of AML, but it's not clear if they increase the risk of ALL.

Klinefelter syndrome is a sex chromosome disorder in which someone assigned male at birth has at least one extra X chromosome. The signs of Kleinfelter syndrome are different depending on the person's age. Signs include small testicles, weak muscles, enlarged breasts, taller than average height and less facial and body hair than most men.

Fanconi anemia affects the bone marrow so it cannot make red blood cells, white blood cells or platelets.

Breathing in benzene

There is convincing evidence that benzene causes AML. People are exposed to benzene by breathing air that has benzene in it. Benzene can be found in:

  • tobacco smoke, including second-hand smoke

  • gasoline fumes and vehicle exhaust
  • glues, adhesives, cleaning products and paint strippers
  • environmental sources such as smoke from forest fires or gas from volcanoes

People who work in industries that use benzene, such as chemical and pharmaceutical companies, may be exposed to higher levels of benzene.

Breathing in formaldehyde

Formaldehyde is a colourless gas. People are exposed to formaldehyde by breathing air that has formaldehyde in it. Formaldehyde can be found in:

  • funeral homes (formaldehyde is used in embalming) and laboratories with preserved specimens

  • the production and use of fertilizer, paper, plywood, plastics, resins and foam insulation
  • household cleaners, medicines and other products as a preservative
  • tobacco smoke, including second-hand smoke

People who work in industries that use formaldehyde, such as agriculture, construction and funeral services, may be exposed to higher levels of formaldehyde.

Smoking

There is convincing evidence that smoking increases the risk of AML. This may be because there is benzene and formaldehyde in tobacco.

Family history

There is convincing evidence that having a family history of AML increases your risk of developing AML. The risk is higher if one of your first-degree relatives (your parent, sibling or child) has been diagnosed.

Children who have an identical twin who develops ALL or AML in the first year of life have a greater risk of developing acute leukemia.

HTLV-1

Infection with the human T-cell leukemia/lymphoma virus, type 1 (HTLV-1) increases the risk of developing T-cell ALL, a rare type of ALL. In many cases, people carrying the virus do not get symptoms or develop health problems from it. Only a few people who have HTLV-1 will develop leukemia.

HTLV-1 is not common in Canada. It is more common in Japan and the Caribbean.

Possible risks

There are some things that may increase your risk for acute leukemia. More research is need to know for sure that they are risks. The following have been linked with ALL, AML or both:

  • obesity
  • contact with pesticides over a long period of time
  • a weakened immune system because of autoimmune disease or having an organ transplant (AML)
  • exposure to diesel fumes

Understanding your cancer risk

To make the decisions that are right for you, ask your doctor questions about risks. Learn how cancer can be prevented and what you can do to reduce your risk.

Expert review and references

  • Canadian Cancer Society | Société canadienne du cancer
  • Abar L, Sobiecki JG, Cariolou M. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Annals of Oncology. 2019: 30(4):528–541.
  • American Cancer Society. Risk Factors for Acute Lymphocytic Leukemia (ALL). February, 2024: https://www.cancer.org/.
  • American Cancer Society. Risk Factors for Acute Myeloid Leukemia (AML). February, 2024: https://www.cancer.org/.
  • Kota, V et al. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. Future Medicine . 2023: 18(36):4017-4029.
  • International Agency for Research on Cancer (IARC). Volume 75: Ionizing Radiation Part 1: X- and Gamma (y)-Radiation, and Neutrons. 2000: http://monographs.iarc.fr/ENG/Monographs/vol75/mono75.pdf.
  • IARC. Volume 76: Some Antiviral and Antineoplastic Drugs,and Other Pharmaceutical Agents. 2000.
  • International Agency for Research on Cancer (IARC). Volume 88: Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol. 2006: http://monographs.iarc.fr/ENG/Monographs/vol88/mono88.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100A: Pharmaceuticals: A Review of Human Carcinogens. 2012: https://publications.iarc.fr/118.
  • International Agency for Research on Cancer (IARC). Volume 100B: Biological agents: A Review of Human Carcinogens. 2012: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100E: Personal Habits and Indoor Combustions. 2012: http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E.pdf.
  • International Agency for Research on Cancer (IARC). Volume 120: Benzene. 2018: http://publications.iarc.fr/576.
  • Kebriaei P, Ravandi F, de Lima M, Champlin R. Management of acute leukemias. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 102:1742–1763..
  • Linet MS, Morton LM, Devesa SS, Dores GM. Leukemias. Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: Kindle version, [chapter 38] https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • Mehta D, Dennis R, Nallamilli S, Vithayathil M, Martinez-Sanchez JM. Correlation between tobacco control policies and mortality of haematological cancers across Europe: An ecological study. Tobacco Prevention & Cessation. 2021: 7:31.
  • Recalde M, Pistillo A, Davila-Batista V, Leitzmann M, Romieu I, et al. Longitudinal body mass index and cancer risk: a cohort study of 2.6 million Catalan adults. Nature Communications. 2023: 14: 3816.
  • National Toxicology Program. Report on Carcinogens. 15 ed. Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service; 2021: https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html.
  • Yang, F, Long N, Anekpuritanang T, Bottomly D, Savage JC, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022: 139(8): 1208-1221.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society